


ANNEXURE I TO CLAUSE 43
Stand Alone Unaudited Financial Results for the half year ended 30th September, 2014

S.No	Particulars	6 months ended 30.09.2014		Corresponding 6 months ended in the previous year 30.09.2013		Year to date figures for the current period ended 30.09.2014		Year to date figures for the previous period ended 30.09.2013		In Rupees	
		Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Previous Accounting year ended 31.03.2014	Audited
1	(a) Net Sales/Income from Operations	336,503,060.00	6,358,168.00	336,503,060.00	6,358,168.00	336,503,060.00	6,358,168.00	336,503,060.00	6,358,168.00	67,058,499.00	
	(b) Other Operating Income										
2	Expenditure										
	a. Increase/decrease in stock in trade and work in progress		203,500.00		203,500.00		203,500.00		203,500.00	1,715,000.00	
	b. Consumption of raw materials	314,595,260.00	2,057,850.00	314,595,260.00	2,057,850.00	314,595,260.00	2,057,850.00	314,595,260.00	2,057,850.00	52,384,656.00	
	c. Purchase of traded goods										
	d. Employee costs & General expenses	2,656,367.00	1,202,540.00	2,656,367.00	1,202,540.00	2,656,367.00	1,202,540.00	2,656,367.00	1,202,540.00	3,613,306.00	
	e. Depreciation	816,957.00	36,308.00	816,957.00	36,308.00	816,957.00	36,308.00	816,957.00	36,308.00	72,616.00	
	f. Other expenditure	4,951,589.00	172,822.00	4,951,589.00	172,822.00	4,951,589.00	172,822.00	4,951,589.00	172,822.00	1,924,314.00	
	g. Total	323,020,173.00	3,673,020.00	323,020,173.00	3,673,020.00	323,020,173.00	3,673,020.00	323,020,173.00	3,673,020.00	59,709,892.00	
	(Any item exceeding 10% of the total expenditure to be shown separately)										
3	Profit from Operations before other Income, Interest & Exceptional Items (1-2)	13,482,887.00	2,685,148.00	13,482,887.00	2,685,148.00	13,482,887.00	2,685,148.00	13,482,887.00	2,685,148.00	7,348,607.00	
4	Other Income	0	0	0	0	0	0	0	0	0	
5	Profit before Interest & Exceptional Items (3+4)	13,482,887.00	2,685,148.00	13,482,887.00	2,685,148.00	13,482,887.00	2,685,148.00	13,482,887.00	2,685,148.00	7,348,607.00	
6	Interest	0	0	0	0	0	0	0	0	0	
7	Profit after Interest but before Exceptional Items (5-6)	13,482,887.00	2,685,148.00	13,482,887.00	2,685,148.00	13,482,887.00	2,685,148.00	13,482,887.00	2,685,148.00	7,348,607.00	
8	Exceptional Items	793,367.00	0	793,367.00	0	793,367.00	0	793,367.00	0	0	
9	Profit (+) / Loss (-) from Ordinary Activities before tax (7+8)	12,689,520.00	2,685,148.00	12,689,520.00	2,685,148.00	12,689,520.00	2,685,148.00	12,689,520.00	2,685,148.00	7,348,607.00	
10	Tax expenses	4,166,212.00	829,700.00	4,166,212.00	829,700.00	4,166,212.00	829,700.00	4,166,212.00	829,700.00	2,292,228.00	
11	Net Profit (+) / Loss (-) from Ordinary Activities after tax (9-10)	8,523,308.00	1,855,448.00	8,523,308.00	1,855,448.00	8,523,308.00	1,855,448.00	8,523,308.00	1,855,448.00	5,056,379.00	
12	Extraordinary Item (net of tax expenses Rs.....)	0	0	0	0	0	0	0	0	0	
13	Net Profit (+) / Loss (-) for the period (11-12)	8,523,308.00	1,855,448.00	8,523,308.00	1,855,448.00	8,523,308.00	1,855,448.00	8,523,308.00	1,855,448.00	5,056,379.00	
14	Paid-up equity share capital (Face Value of the Share shall be indicated)	52181500	31181500	52181500	31181500	52181500	31181500	52181500	31181500	52181500	
		Rs.10/-	Rs.10/-	Rs.10/-	Rs.10/-	Rs.10/-	Rs.10/-	Rs.10/-	Rs.10/-	Rs.10/-	
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year										
16	Earnings Per Share (EPS)										
	(a) Basic and diluted EPS before extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	1.63	0.60	1.63	0.60	1.63	0.60	1.63	0.60	0.67	
	(b) Basic and diluted EPS after extraordinary items for the period, for the year to date and for the previous year (not to be annualized)										



For Oceanaa Biotech Industries Limited

Director

17 Public shareholding					
- Number of shares	2,100,300				2,100,300
- Percentage of shareholding	40.25%				40.25%
18 Promoters and Promoter Group Shareholding					
a) Pledged/ Encumbered					
- Number of shares					
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil				Nil
- Percentage of shares (as a % of the total share capital of the issuer)					
b) Non - encumbered					
- Number of shares	3117850				3117850
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%				100%
- Percentage of shares (as a % of the total share capital of the issuer)	59.75%				59.75%
c) Others					
		0.02%		0.02%	

Particulars	6 months ended 30.09.2014
Investors Complaints	Nil
Previous at the beginning of the Quarter	Nil
Received during quarter	Nil
Disposed during quarter	Nil
Remaining unresolved at the end of the quarter	Nil

* strike off whichever is not applicable

Notes:

1. The unaudited Financial results were reviewed by the Audit Committee and taken on record by the Board of directors at their meeting held on 5th November, 2014.
2. The Statutory Auditors of the Company have carried out limited review for the Half year ended 30.09.2014
3. The Company commenced operations of Hatchery testing of seed and shrimps (Laboratory) on 25th August, 2014.
4. The Company collected Rs.2.10 crores through Initial Public Offering.Out of which the entire amount has been utilized in setting up of food testing laboratory and commencement of business operations thereof
5. There were no Investors' Complaints pending/received during the period.



For Oceanaa Biotek Industries Limited

(W) Director

Annexure III to Clause 43 Reporting of Segment wise Revenue, Results and Capital Employed along with the half yearly results for 30th September, 2014						
Particulars	6 months ended 30.09.2014		Corresponding 6 months ended 30.09.2013		Year to date figures for current period ended 30.09.2013	
	Unaudited		Audited		Audited	
					Year to date figures for current period ended 30.09.2014	
1. Segment Revenue (net sale/income from each segment should be disclosed under this head)						
a) Segment - Trading	336,312,520.00		5,109,049.00		5,109,049.00	59,213,570.00
b) Segment - Contract	-		1,249,119.00		1,249,119.00	6,609,049.00
c) Segment - Stickers	190,540.00		-		-	1,235,880.00
d) Segment - Lab Testing charges	336,503,060.00		6,358,168.00		6,358,168.00	67,058,499.00
Total						
Less: Inter Segment Revenue						
Net Sales / Income From Operations	336,503,060.00		6,358,168.00		6,358,168.00	67,058,499.00
2. Segment Results (Profit)/Loss						
(-) before tax and interest from Each segment						
a) Segment - Trading	18,089,370.00		2,849,565.15		2,849,565.15	1,676,379.37
b) Segment - Contract	-		3,650,709.96		3,650,709.96	3,924,222.63
c) Segment - Stickers	-		174,510.16		174,510.16	161,271.15
d) Segment - Lab Testing charges	(4,606,483.00)		(4,606,483.00)		(4,606,483.00)	
Total	13,482,887.00		6,674,785.27		6,674,785.27	5,761,873.15
Less: i) Interest						
ii) other Unallocable expenditure						
net off	13,482,887.00		6,674,785.27		6,674,785.27	5,761,873.15
iii) Un-allocable Income						
Total Profit Before Tax	13,482,887.00		6,674,785.27		6,674,785.27	5,761,873.15
3. Capital Employed (Segment assets - Segment Liabilities)						
a) Segment - Trading	54,334,508.90		36,000.00		36,000.00	3,884,006.00
b) Segment - Contract						
c) Segment - Stickers						
d) Segment - Lab Testing charges	10,924,244.00					36,000.00
Total	65,258,752.90		36,000.00		36,000.00	3,920,006.00

* strike off whichever is not applicable

Profit/loss before tax and after interest in case of segments having operations which are primarily of financial nature.

** Other than the interest pertaining to the segments having operations which are primarily of financial nature.

Notes:

(a) Segment Revenue, Segment Results, Segment assets and Segment liabilities shall have the same meaning as defined in the Accounting Standards on Segment Reporting (AS-17) issued by ICAI / Company (Accounting Standards) Rules, 2006.

(b) The above information shall be furnished for each of the reportable primary segments as identified in accordance with AS-17, issued by ICAI / Company (Accounting Standards) Rules, 2006.

For Oceanaa Biotech Industries Limited



Director

OCEANAA BIOTEK INDUSTRIES LIMITED

CIN: U15549TN2005PLC057919

NO. 15, ZACKARIA COLONY, 4TH STREET, CHOOLAIMEDU, CHENNAI – 600 094, TAMIL NADU,


Annexure VI (Clause 43)

(In Rupees) ₹

Particulars	6 months ended 30.09.2014	Corresponding 6 months ended in the previous year 30.09.2013
	Unaudited	Audited
SHAREHOLDERS' FUNDS:		
(a) Capital	52,181,500.00	31,181,500.00
(b) Reserves and Surplus	11,420,632.00	1,272,850.00
LOAN FUNDS	-	
FIXED ASSETS	52,085,542.00	322,301.00
INVESTMENTS	-	-
CURRENT ASSETS, LOANS AND ADVANCES		
(a) Inventories	-	1,511,500.00
(b) Sundry Debtors	70,083,985.00	1,465,846.00
(c) Cash and Bank balances	1,441,086.00	604,025.00
(d) Other current assets	2,499,315.00	1,489,309.00
(e) Loans and Advances	15,571,853.00	29,944,170.00
Less: Current Liabilities and Provisions		
(a) Liabilities	73,913,032.00	1,857,573.00
(b) Provisions	4,176,894.00	970,229.00
MISCELLANEOUS EXPENDITURE WRITTEN OFF (NOT OR ADJUSTED)	10,277.00	-
PROFIT AND LOSS ACCOUNT		-
TOTAL	141,681,781.00	35,337,151.00



For Oceanaa Biotek Industries Limited


Director



Date: 05/11/2014

Annexure IV to Clause 43


Limited Review Report

Review Report to
The Board of Directors
Oceanaa Biotek Industries Limited

We have reviewed the accompanying statement of unaudited financial results of **Oceanaa Biotek Industries Limited** for the period ended 30th September, 2014 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Issuer's Management and has been approved by the Board of Directors/committee of Board of Directors of the Issuer. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Issuer's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 43 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.



MEMBERSHIP No: 9274